About
OncoC4 develops innovative immuno-oncology therapies using innate and adaptive immune checkpoint targets such as CTLA-4, PD-1/VEGF, Siglec, and CD24 to create safer and more effective treatments for hard-to-treat cancers and Alzheimer’s disease.
Explore OncoC4's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.